Quick Answer
Roivant Sciences Ltd. reported R&D Expense of $550.41 million for fiscal year 2025.
Roivant Sciences Ltd. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $550.41M | +25.1% |
| 2024 | $439.91M | -3.1% |
| 2023 | $454.06M | -6.0% |
| 2022 | $483.04M | +104.1% |
| 2021 | $236.63M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| December 31, 2025 | $165.38M | +16.8% | +0.5% |
| September 30, 2025 | $164.57M | +15.0% | +7.6% |
| June 30, 2025 | $152.92M | +26.9% | +8.0% |
| December 31, 2024 | $141.59M | +30.9% | -1.0% |
| September 30, 2024 | $143.07M | +24.6% | +18.7% |
| June 30, 2024 | $120.51M | -3.7% | +11.4% |
| December 31, 2023 | $108.15M | -13.8% | -5.8% |
| September 30, 2023 | $114.79M | -13.0% | -8.3% |
- Roivant Sciences Ltd. showed an increase of +25.1% in R&D Expense compared to the prior fiscal year.
- Over the 2021–2025 period, Roivant Sciences Ltd.’s r&d expense has grown by 132.6% (from $236.63 million to $550.41 million).
- The most recent figure is from Roivant Sciences Ltd.’s fiscal year 2024 report (Form 10-K), filed with the SEC on May 29, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: